[1] Lindroos M, Kupari M, Heikkilä J, Tilvis R. Prevalence of aortic valve abnormalities in the elderly: an echocardiographic study of a random population sample. J Am Coll Cardiol 1993; 21: 1220−1225. doi: 10.1016/0735-1097(93)90249-Z [2] [3] Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. Eur J Cardiothorac Surg 2021; 60: 727−800. doi: 10.1093/ejcts/ezab389 [4] Leon MB, Smith CR, Mack M, et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med 2010; 363: 1597−1607. doi: 10.1056/NEJMoa1008232 [5] Smith CR, Leon MB, Mack MJ, et al. Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med 2011; 364: 2187−2198. doi: 10.1056/NEJMoa1103510 [6] Leon MB, Smith CR, Mack MJ, et al. Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. New Eng J Med 2016; 374: 1609−1620. doi: 10.1056/NEJMoa1514616 [7] Reardon MJ, Van Mieghem NM, Popma JJ, et al. Surgical or transcatheter aortic-valve replacement in intermediate-risk patients. New Eng J Med 2017; 376: 1321−1331. doi: 10.1056/NEJMoa1700456 [8]

Baron SJ, Arnold SV, Wang K, et al. Health status benefits of transcatheter vs. surgical aortic valve replacement in patients with severe aortic stenosis at intermediate surgical risk: results from the PARTNER 2 randomized clinical trial. JAMA Cardiol 2017; 2: 837−845.

[9] Mylotte D, Osnabrugge RLJ, Windecker S, et al. Transcatheter aortic valve replacement in Europe: adoption trends and factors influencing device utilization. J Am Coll Cardiol 2013; 62: 210−219. doi: 10.1016/j.jacc.2013.03.074 [10] [11]

Sakiyalak P, Slisatkorn W, Pornratanarangsi S, et al. Transcatheter aortic valve implantation (TAVI): first case in Thailand. J Med Assoc Thai 2012; 95: 124−128.

[12] Wongpraparut NS, Jakrapanichakul D, Maneesai A, et al. Ten years’ experience of transcatheter aortic valve replacement at the Faculty of Medicine Siriraj Hospital: transapical vs. transfemoral approach. J Med Assoc Thai 2021; 104: 846−852. doi: 10.35755/jmedassocthai.2021.05.12353 [13] Chotnoppharatphatthara P, Yoodee V, Taesotikul S, et al. Transcatheter aortic valve implantation in patients with severe symptomatic aortic valve stenosis: systematic review of cost-effectiveness analysis. Eur J Health Econ. Published Online First: Jun 16, 2022; DOI: 10.1007/s10198-022-01477-3. [14] Inoue S, Nakao K, Hanyu M, et al. Cost-effectiveness of transcatheter aortic valve implantation using a balloon-expandable valve in Japan: experience from the Japanese pilot health technology assessment. Value Health Reg Issues 2020; 21: 82−90. doi: 10.1016/j.vhri.2019.07.013 [15] Kodera S, Kiyosue A, Ando J, Komuro I. Cost effectiveness of transcatheter aortic valve implantation in patients with aortic stenosis in Japan. J Cardiol 2018; 71: 223−229. doi: 10.1016/j.jjcc.2017.10.008 [16] Kuntjoro I, Tay E, Hon J, Yip J, Kong W, Poh KK, et al. Cost-effectiveness of transcatheter aortic valve implantation in intermediate and low risk severe aortic stenosis patients in Singapore. Ann Acad Med Singap 2020; 49: 423−433. doi: 10.47102/annals-acadmedsg.2019198 [17] Leelahavarong P, Doungthipsirikul S, Kumluang S, et al. Health technology assessment in Thailand: institutionalization and contribution to healthcare decision making: review of literature. Int J Technol Assess Health Care 2019; 35(6): 467−473. doi: 10.1017/S0266462319000321 [18] Chalkidou K, Glassman A, Marten R, et al. Priority-setting for achieving universal health coverage. Bull World Health Organ 2016; 94: 462−467. doi: 10.2471/BLT.15.155721 [19] Mohara A, Youngkong S, Velasco RP, et al. Using health technology assessment for informing coverage decisions in Thailand. J Comp Eff Res 2012; 1: 137−146. doi: 10.2217/cer.12.10 [20]

O’Brien SM, Shahian DM, Filardo G, et al. The Society of Thoracic Surgeons 2008 cardiac surgery risk models: part 2--isolated valve surgery. Ann Thorac Surg 2009; 88(1 Suppl): S23-S42.

[21] Adams DH, Popma JJ, Reardon MJ, et al. Transcatheter aortic-valve replacement with a self-expanding prosthesis. New Eng J Med 2014; 370: 1790−1798. doi: 10.1056/NEJMoa1400590 [22] [23] Strange G, Stewart S, Celermajer D, et al. Poor long-term survival in patients with moderate aortic stenosis. J Am Coll Cardiol 2019; 74: 1851−1863. doi: 10.1016/j.jacc.2019.08.004 [24]

Riewpaiboon A. Measurement of costs for health economic evaluation. J Med Assoc Thai 2014; 97(Suppl 5): S17−S26.

[25] [26] [27]

Permsuwan U, Guntawongwan K, Buddhawongsa P. Handling time in economic evaluation studies. J Med Assoc Thai 2014; 97 Suppl 5: S50-S58

[28]

Thavorncharoensap M, Teerawattananon Y, Natanant S, et al. Estimating the willingness to pay for a quality-adjusted life year in Thailand: does the context of health gain matter? Clinicoecon Outcomes Res 2013; 5: 29−36.

[29]

Briggs AH. Handling uncertainty in cost-effectiveness models. PharmacoEconomics. 2000; 17: 479-500.

[30] Ribera A, Slof J, Andrea R, et al. Transfemoral transcatheter aortic valve replacement compared with surgical replacement in patients with severe aortic stenosis and comparable risk: cost-utility and its determinants. Int J Cardiol 2015; 182: 321−328. doi: 10.1016/j.ijcard.2014.12.109 [31] Tam DY, Hughes A, Fremes SE, et al. A cost-utility analysis of transcatheter versus surgical aortic valve replacement for the treatment of aortic stenosis in the population with intermediate surgical risk. J Thorac Cardiovasc Surg 2018; 155: 1978−1988.e1. doi: 10.1016/j.jtcvs.2017.11.112 [32] Baron SJ, Wang K, House JA, et al. Cost-effectiveness of transcatheter versus surgical aortic valve replacement in patients with severe aortic stenosis at intermediate risk. Circulation 2019; 139: 877−888. doi: 10.1161/CIRCULATIONAHA.118.035236 [33] Goodall G, Lamotte M, Ramos M, et al. Cost-effectiveness analysis of the SAPIEN 3 TAVI valve compared with surgery in intermediate-risk patients. J Med Econ 2019; 22: 289−296. doi: 10.1080/13696998.2018.1559600 [34] Zhou J, Liew D, Duffy SJ, et al. Cost-effectiveness of transcatheter aortic valve implantation compared to surgical aortic valve replacement in the intermediate surgical risk population. Int J Cardiol 2019; 294: 17−22. doi: 10.1016/j.ijcard.2019.06.057 [35] Tarride JE, Luong T, Goodall G, et al. A Canadian cost-effectiveness analysis of SAPIEN 3 transcatheter aortic valve implantation compared with surgery, in intermediate and high-risk severe aortic stenosis patients. Clinicoecon Outcomes Res 2019; 11: 477−486. doi: 10.2147/CEOR.S208107 [36] Makkar RR, Thourani VH, Mack MJ, et al. Five-year outcomes of transcatheter or surgical aortic-valve replacement. New Eng J Med 2020; 382: 799−809. doi: 10.1056/NEJMoa1910555